Parallel changes in serum proteins and diffusion tensor imaging in methamphetamine-associated psychosis

scientific article

Parallel changes in serum proteins and diffusion tensor imaging in methamphetamine-associated psychosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1084131682
P356DOI10.1038/SREP43777
P932PMC publication ID5333148
P698PubMed publication ID28252112

P50authorDan J. SteinQ5213742
Sabine BahnQ28469526
Anne UhlmannQ56987358
Man ChanQ56989966
Dalila PintoQ38112120
P2093author name stringMichael S Breen
Sureyya Ozcan
P2860cites workThe dopamine hypothesis of schizophrenia: version III--the final common pathwayQ22242827
The cerebellum and addiction: insights gained from neuroimaging researchQ26828743
Fornix as an imaging marker for episodic memory deficits in healthy aging and in various neurological disordersQ26864417
A review of the clinical pharmacology of methamphetamineQ28244252
The positive and negative syndrome scale (PANSS) for schizophreniaQ28301751
Diffusion Tensor Imaging of the BrainQ28972504
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion dataQ29615647
The basis of anisotropic water diffusion in the nervous system - a technical reviewQ29616528
Simultaneous inference in general parametric modelsQ29619454
A revised version of the psychoticism scaleQ30051509
Skyline: an open source document editor for creating and analyzing targeted proteomics experimentsQ30080030
White-matter abnormalities in brain during early abstinence from methamphetamine abuseQ33643608
Biomarker Development for Brain-Based Disorders: Recent Progress in PsychiatryQ34010400
Chlorogenic and caftaric acids in liver toxicity and oxidative stress induced by methamphetamineQ34022333
Diffusion tensor imaging in schizophreniaQ57403941
Recent updates on drug abuse analyzed by neuroproteomics studies: Cocaine, Methamphetamine and MDMAQ58114574
Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selectionQ60181562
Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samplesQ80720266
Volume reductions in frontopolar and left perisylvian cortices in methamphetamine induced psychosisQ86829146
Towards a blood-based diagnostic panel for bipolar disorderQ48073166
Discovery of serum biomarkers predicting development of a subsequent depressive episode in social anxiety disorder.Q48084166
Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysisQ48156818
Decreased levels of apolipoprotein A-I in plasma of schizophrenic patientsQ48339668
Decreased frontal white-matter integrity in abstinent methamphetamine abusersQ48347308
Serum proteomics of methamphetamine addicts and up-regulation of complement factor H related to methamphetamine addictionQ48417072
Virtual in vivo interactive dissection of white matter fasciculi in the human brain.Q48426204
Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorderQ48557994
Reduced amygdala and hippocampal volumes in patients with methamphetamine psychosis.Q49017708
Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis.Q51105028
Fiber tract-based atlas of human white matter anatomyQ34279968
Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onsetQ34484906
Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designsQ34486911
Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individualsQ34492046
Apolipoproteins in the brain: implications for neurological and psychiatric disordersQ34680878
The neurobiology of apolipoproteins in psychiatric disordersQ34995089
Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS projectQ35096541
Protein significance analysis in selected reaction monitoring (SRM) measurementsQ35878777
Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?Q36049902
variancePartition: interpreting drivers of variation in complex gene expression studies.Q36203417
Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorderQ36351715
Evidence for white matter abnormalities in schizophreniaQ36460207
Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM templateQ36782356
Proteomic profiling in schizophrenia: enabling stratification for more effective treatmentQ36998471
Prevalence of psychotic symptoms in substance users: a comparison across substancesQ37346851
Serum proteomic profiling of major depressive disorderQ37347574
Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing reportQ37349915
Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndromeQ37528958
The neurobiology of methamphetamine induced psychosisQ38237633
Applications of blood-based protein biomarker strategies in the study of psychiatric disordersQ38244876
Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus.Q38399332
Synaptic vesicle dynamic changes in a model of fragile X.Q38693916
Systematic review of blood transcriptome profiling in neuropsychiatric disorders: guidelines for biomarker discoveryQ38819329
White matter microstructure and impulsivity in methamphetamine dependence with and without a history of psychosisQ38900777
Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.Q39139419
Psychosis post corona radiata and lentiform nucleus infarctionQ39757070
Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophreniaQ40834916
Stress and lipoprotein metabolism: modulators and mechanismsQ40865498
Targeted multiplexed selected reaction monitoring analysis evaluates protein expression changes of molecular risk factors for major psychiatric disordersQ41651452
Microstructural Changes of Anterior Corona Radiata in Bipolar DepressionQ42103235
Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomographyQ42285641
Effects of hemoconcentration and sympathetic activation on serum lipid responses to brief mental stressQ44078648
Functional magnetic resonance imaging of methamphetamine cravingQ46063734
A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteinsQ46308632
Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in TaiwanQ46554056
(1)H-magnetic resonance spectroscopy ((1)H-MRS) in methamphetamine dependence and methamphetamine induced psychosisQ46732068
Fronto-temporal alterations and affect regulation in methamphetamine dependence with and without a history of psychosisQ47593679
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectdiffusion tensor imagingQ30088257
P304page(s)43777
P577publication date2017-03-02
P1433published inScientific ReportsQ2261792
P1476titleParallel changes in serum proteins and diffusion tensor imaging in methamphetamine-associated psychosis
P478volume7

Reverse relations

Q92806896Methamphetamine-associated psychosis: Clinical presentation, biological basis, and treatment optionscites workP2860

Search more.